Consequences of counterfeit pharmaceutical product sales
Recently, both the FDA and EMA have raised concerns about counterfeit drug products, including GLP-1s used for weight loss and diabetes, being marketed in the...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA’s life sciences litigation support services are grounded in a comprehensive understanding of pharmaceutical, biotechnology, medical device, and diagnostic markets. For more than 30 years, our experts have consulted with major life science companies, law firms, and regulatory agencies around the globe. We provide clients with the industry and analytical expertise needed to solve our clients’ most complex issues.
CRA has a reputation for delivering rigorous analysis and expert testimony. Economic expertise is complemented by experience assisting life sciences companies with business and policy issues. This combination allows CRA to provide effective expert testimony and support.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comRecently, both the FDA and EMA have raised concerns about counterfeit drug products, including GLP-1s used for weight loss and diabetes, being marketed in the...
Branded pharmaceutical manufacturers are required by law to list all patents in the Orange Book that cover an approved drug product. However,...
Greg Bell is a panelist during the session titled “Navigating Life Sciences disputes. An arbitrator’s perspective.” For more information on this event, click...
CRA is a proud sponsor of the premier event advancing women in tech and IP law. For more information on this event, click here.


